Search by Drug Name or NDC
NDC 50090-2623-01 Terazosin 2 mg/1 Details
Terazosin 2 mg/1
Terazosin is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by A-S Medication Solutions. The primary component is TERAZOSIN HYDROCHLORIDE.
MedlinePlus Drug Summary
Terazosin is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia or BPH), which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying), painful urination, and urinary frequency and urgency. It also is used alone or in combination with other medications to treat high blood pressure. Terazosin is in a class of medications called alpha-blockers. It relieves the symptoms of BPH by relaxing the muscles of the bladder and prostate. It lowers blood pressure by relaxing the blood vessels so that blood can flow more easily through the body. High blood pressure is a common condition, and when not treated it can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 50090-2623-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Terazosin
Product Information
| NDC | 50090-2623 |
|---|---|
| Product ID | 50090-2623_75e28a8b-3814-4df0-9321-f79628448308 |
| Associated GPIs | 36202040100110 |
| GCN Sequence Number | 022650 |
| GCN Sequence Number Description | terazosin HCl CAPSULE 2 MG ORAL |
| HIC3 | J7B |
| HIC3 Description | ALPHA-ADRENERGIC BLOCKING AGENTS |
| GCN | 47125 |
| HICL Sequence Number | 000094 |
| HICL Sequence Number Description | TERAZOSIN HCL |
| Brand/Generic | Generic |
| Proprietary Name | Terazosin |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Terazosin Hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 2 |
| Active Ingredient Units | mg/1 |
| Substance Name | TERAZOSIN HYDROCHLORIDE |
| Labeler Name | A-S Medication Solutions |
| Pharmaceutical Class | Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA075317 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 50090-2623-01 (50090262301)
| NDC Package Code | 50090-2623-1 |
|---|---|
| Billing NDC | 50090262301 |
| Package | 90 CAPSULE in 1 BOTTLE (50090-2623-1) |
| Marketing Start Date | 2018-08-30 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |